PvGAP: Development of a globally-applicable, highly-multiplexed microhaplotype amplicon panel for *Plasmodium vivax*

Alfred Hubbard[1], Edwin Solares[2], Lauren Bradley[3], Brook Jeang[3], Delenasaw Yewhalaw[4,5], Daniel Janies[6], Eugenia Lo[7], Guiyun Yan[3], Elizabeth Hemming-Schroeder[8]

1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
2. Department of Computer Science and Engineering, UC San Diego, San Diego, California, USA
3. Department of Population Health & Disease Prevention, UC Irvine Wen School of Population and Public Health, Irvine, California, USA
4. School of Medical Laboratory Sciences, Jimma University, Jimma, Ethiopia
5. Tropical and Infectious Diseases Research Center, Jimma University, Jimma, Ethiopia
6. Department of Bioinformatics and Genomics, University of North Carolina at Charlotte, Charlotte, North Carolina, USA
7. Department of Microbiology & Immunology, Drexel University, Philadelphia, Pennsylvania, USA
8. College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado, USA

Abstract

Background

Plasmodium vivax malaria research has yet to fully benefit from the advances in genomic surveillance that have revolutionized *P. falciparum* epidemiology. Closing this gap is critical because genomic tools are necessary to monitor the spread of drug resistance, classify infections as local or imported, and distinguish reinfection,

recrudescence, and relapse. To achieve these objectives, microhaplotype marker

panels that allow powerful genotyping of polyclonal infections are needed.

Methods

We designed a Globally-applicable Amplicon Panel for *P. vivax* (PvGAP), selecting

targets based on both genetic diversity and genetic distance from each other to

maximize discriminatory capability between geographic regions. We evaluated this

panel with field samples from Ethiopia and *in silico* using whole genomes from the

MalariaGEN Pv4 database.

Results

PvGAP has 80 high diversity targets suitable for population genomics and eight targets

of specific epidemiological interest, such as putative markers of drug resistance. We

demonstrate PvGAP achieves robust amplification with field data and that it provides

competitive accuracy for relatedness inference in three disparate geographic regions.

Conclusions

PvGAP joins existing *P. vivax* panels as a cost effective and practical option for

genomic epidemiology of this neglected disease. It will support drug resistance

surveillance, discrimination of local and imported cases, and it may aid in separating

reinfection, recrudescence, and relapse in therapeutic efficacy studies, all critical needs

of National Malaria Control Programs.

Background

Plasmodium vivax remains understudied compared to *P. falciparum*, despite the fact

that it can cause severe and life-threatening malaria (Anstey et al., 2012) and is

endemic in tropical regions throughout the world, including most of Africa (Twohig et al.,

2019). Improving our understanding of *P. vivax* epidemiology is a key step to planning

effective antimalarial interventions and ultimately eliminating malaria.

Population genomics is one powerful approach for enhancing our collective

understanding of malaria epidemiology. Genomic data from malaria parasites can be

used to assess transmission between geographic locations and can support modeling of

relapse, recrudescence, and reinfection (Neafsey et al., 2021). However, the application

of population genomics to malaria epidemiology is limited by technical constraints and

costs. Classical biallelic SNP assays have low sensitivity to detect multiple parasite

strains and parasite diversity within a host (Koepfli & Mueller, 2017). On the other hand,

whole genome sequencing (WGS) data provides comprehensive coverage, but is costly

to produce (Tessema et al., 2022) and store (Neafsey et al., 2021).

A cost-effective alternative with high sensitivity to detect minority clones is targeted

deep sequencing of genetically-diverse amplicons (Koepfli & Mueller, 2017; Tessema et

al., 2022). This approach is particularly effective when used to assess multiallelic

microhaplotypes, meaning targets that contain two or more SNPs. Microhaplotype

markers have been shown to provide higher power for relatedness inference than

biallelic SNPs, particularly in the case of polyclonal infections (Tessema et al., 2022).

The benefits of microhaplotype panels for understanding genetic relatedness and

diversity have already been demonstrated in *P. falciparum* (LaVerriere et al., 2022;

Tessema et al., 2022).

Several microhaplotype panels have been or soon will be published for *P. vivax*.

Particularly noteworthy are the Kleinecke et al. (2025) and PvGTSeq (Manrique-

Valverde et al., 2025) panels, which both contain putative markers of drug resistance

and numerous high diversity targets (93 for Kleinecke et al. and 213 for PvGTSeq). A

handful of other panels have been developed with smaller sets of microhaplotypes

(Kattenberg et al., 2022, 2024; Popkin-Hall et al., 2024; Rosado et al., 2025). Given that

biallelic markers, which comprise most of the Kattenberg et al. (2022), Kattenberg et al.

(2024), and Popkin-Hall et al. (2024) panels, are fundamentally limited in the presence

of polyclonal infections (Tessema et al., 2022) and the small size of the Rosado et al.

(2025) panel (11 targets), these panels are likely to have less power for relatedness

estimation than the PvGTSeq and Kleinecke et al. panels. They may retain sufficient

power in certain settings and for other applications such as estimating the number of

unique strains in an infection (i.e., the complexity of infection).

This paper describes the design and validation of a *Plasmodium vivax* Globally-

applicable Amplicon Panel (PvGAP) that is similar in scope to the Kleinecke et al.

(2025) and PvGTSeq (Manrique-Valverde et al., 2025) panels. PvGAP consists of 80

high-diversity microhaplotype markers, seven putative drug resistance markers, and a

section of *pvdbp* (*P. vivax* Duffy binding protein). The associated library preparation

protocol is relatively low cost and uses non-proprietary reagents. Therefore, PvGAP is a

powerful and flexible addition to the *P. vivax* population genomics toolkit that should suit

a variety of epidemiological applications.

Methods

Panel design

Whole genome sequence data from 198 *P. vivax* isolates from eight countries were downloaded from NCBI (Table 1). Reads were aligned to the PvP01 reference genome (Auburn et al., 2016) and variants were called using standard bioinformatic pipelines. Candidate loci were identified using a sliding-window method adapted from Tessema et al. (2022). Genomic windows were filtered to remove repetitive regions, indels, and loci lacking within-country polymorphism. Remaining windows were evaluated based on within-country nucleotide diversity (π) and population differentiation (FST) among countries. Windows with high diversity and/or strong genetic structuring were prioritized across chromosomes, yielding 278 candidate targets distributed across the genome. Detailed bioinformatic methods, filtering criteria, and marker selection procedures are provided in Supplemental Text 1.

Table 1: *P. vivax* genomes used in panel design

Country	No. of Genomes	Reference
Cambodia	31	Parobek et al. (2016)
China	28	Chen et al. (2017) Shen et al. (2017)
Colombia	8	Winter et al. (2015)
Ethiopia	33	Auburn et al. (2019) Lo et al. (2019)
Madagascar	9	Menard et al. (2013)

Malaysia	30	Auburn et al. (2018)
Panama	29	Accession: PRJNA655141
Peru	30	Cowell et al. (2018)

These targets were submitted to GTseek LLC (Twin Falls, ID, USA) for multiplex primer

design optimized to minimize primer crosstalk (Campbell et al., 2015). After initial

sequencing tests, poorly performing targets were removed, resulting in a final set of 80

loci. Eight additional loci targeting *pvdbp* and putative drug resistance markers were

added to the panel (Table 2), resulting in a final panel of 88 loci (Supplemental Data 1).

Table 2: *P. vivax* genes of particular epidemiological interest

Gene name	Gene ID	Chromosome	Start*	End*
pvdbp	PVP01_0623800	PvP01_06_v1	983467	983623
pvcrt	PVP01_0109300	PvP01_01_v1	442085	442281
pvdhfr	PVP01_0526600	PvP01_05_v1	1077441	1077602
pvdhps	PVP01_1429500	PvP01_14_v1	1270726	1270916
pvdhps	PVP01_1429500	PvP01_14_v1	1270343	1270530
pvk13	PVP01_1211100	PvP01_12_v1	485037	485238
pvk13	PVP01_1211100	PvP01_12_v1	486524	486684
pvmdr1	PVP01_1010900	PvP01_10_v1	479798	479986

118   * Start and end coordinates are zero-based

Panel evaluation with field samples

Two sets of field samples were used to evaluate sequencing performance of the panel.

First, ten high-parasitemia samples (six dried blood spot (DBS) and four whole blood

samples) were processed using multiple laboratory workflows to assess how different

DNA extraction methods (Chelex/saponin versus spin column kit) and enrichment

strategies (selective whole genome amplification or SWGA versus targeted pre-

amplification) affected sequencing outcomes. A detailed description of these procedures

is provided in Supplemental Text 2. Second, to assess how parasite density influences

sequencing output, serial dilutions were generated from five high-parasitemia DBS

samples to mimic realistic low-parasitemia infections. The procedures and results of this

analysis are described in the main text below.

Sample collection

131 The samples used for the serial dilutions were gathered as part of a sub-Saharan Africa

132 International Center for Excellence for Malaria Research (ICEMR) project (Githure et al.,

133 2022; Yan et al., 2022). They were collected as DBS through both passive case

134 detection and community cross-sectional surveys from two sites in Southwestern

135 Ethiopia. Details on sample collection may be found in Getachew et al. (2023).

Library preparation and sequencing

DNA was extracted from DBS using the Monarch Spin gDNA extraction kit (New

England Biolabs). Briefly, a 6 mm DBS punch was lysed and genomic DNA purified

following the manufacturer's protocol with minor modifications, with DNA eluted in 35 µL

of TE buffer. Parasite DNA concentration was quantified by qPCR using primers and

probes described by Lee et al. (2015) and a standard curve generated from serial

dilutions of the *P. vivax* Sal I Sau3AI gDNA library (MRA-40, BEI Resources). Additional

details of DNA extraction and quantification are provided in Supplemental Text 1.

Following quantification, samples were diluted to target parasite DNA concentrations of

1000, 500, 250, 100, 50, and 10 copies/µl. To generate serial dilutions that more closely

mimic natural infections with low parasitemia (i.e., similar ratios of human to parasite

gDNA), gDNA was extracted from uninfected human DBS following the same

purification protocol and used as the diluent. Because a gDNA library was used as the

quantification standard due to limited availability of parasite material, copy number

estimates cannot be directly translated to parasitemia. However, assuming an

approximate extraction efficiency of 30% and an input volume of 10 µL of whole blood

per 6 mm DBS punch, a measured concentration of 10 parasite copies/µL of eluate

would correspond to approximately 11.7 parasites/µL of whole blood. This estimate

should be interpreted as an approximation given variability in DBS blood volume and

extraction recovery.

The library preparation protocol is described in detail in Supplemental Text 3. In brief, it

consists of SWGA, adapted from Oyola et al. (2016) and Cowell et al. (2017), to

increase the density of parasite DNA; an adapted version of the GT-seq PCR protocol

to affix primers (see Campbell et al. (2015) for the original technique and LaVerriere et

al. (2022) for a previous application to *P. falciparum*); and application of Nate's Plates

kits (GTseek LLC) to affix dual indexing tags and normalize sequence quantity across

samples. Various QC assays are performed after each step and on the final libraries, as

described in Supplemental Text 3. Sequencing was performed on an Illumina MiSeq,

using the Reagent Kit v2 500 cycles kit in paired-end mode with a 10% PhiX spike in.

Samples were amplified and sequenced in triplicate.

Bioinformatics analysis

The malaria amplicon pipeline published alongside LaVerriere et al. (2022) was used to

extract and filter microhaplotypes, using primer and reference files appropriate for our *P.*

vivax panel (Supplemental Data 2). This pipeline uses the Divisive Amplicon Denoising

Algorithm (DADA2; Callahan et al., 2016) as the core method for identifying and filtering

amplicons. The pipeline then applies a handful of postprocessing steps to remove likely

sequencing artifacts and chimeras.

Amplicons with fewer than five reads or a within-sample allele frequency (WSAF) below

1% were filtered out. Lin's concordance correlation coefficient was computed among

replicate pairs with the DescTools R package (Signorell, 2025).

Panel evaluation with paneljudge and MalariaGEN data

Data preparation

To assess the utility of the panel for population genetics and genomic epidemiology,

whole genome sequences from the MalariaGEN Pv4 project (MalariaGEN et al., 2022)

were downloaded and virtual microhaplotypes were extracted. Variants that failed the

QC process of the MalariaGEN authors (FILTER="PASS" in the VCF) were excluded.

Samples with an F_{WS} below 0.95 were removed, as these are considered to be

polyclonal (Auburn et al., 2012). Finally, samples from longitudinal studies and returning

travelers were removed. From the remaining samples, three populations were selected

based on sample size and representation of distinct regions: Cambodia and Vietnam in

2015 and 2016 (n=72); Brazil, Colombia, and Peru in 2013 and 2014 (n=43); and

Ethiopia in 2013 (n=49).

The remaining variants were filtered to the genomic regions represented in PvGAP

using bcftools view (Danecek et al., 2021). Haplotype sequences were obtained for

each sample and locus with bcftools consensus (Danecek et al., 2021), using the

PvP01 reference genome (Auburn et al., 2016). To enable comparison with other

amplicon panels, the diversity targets of the Kleinecke et al. (2025) and PvGTSeq

(Manrique-Valverde et al., 2025) panels were extracted with the same methods. Other

P. vivax microhaplotype panels were excluded from this analysis because they either

lack diverse microhaplotype targets (Kattenberg et al., 2022, 2024; Popkin-Hall et al.,

2024) or are considerably smaller than the three panels included in the evaluation

(Rosado et al., 2025).

paneljudge analysis

For each population, the allele frequencies of all panel targets were calculated with the

Dcifer R package (Gerlovina et al., 2022). Cardinality (the number of unique alleles at a

locus) and effective cardinality (the number of unique alleles adjusted for their

frequency; see Taylor et al., 2019) were calculated from these frequencies with the

paneljudge R package (https://github.com/aimeertaylor/paneljudge; v0.0.0.9). The

paneljudge package was also used to simulate pairwise relatedness estimates for each

panel under various true values of r: 0.01, 0.05, 0.1, 0.15, 0.2, 0.25, 0.5, 0.75, and 0.99.

These simulations were performed with 100 sample pairs drawn from each population,

100 bootstrap replicates, and a switch-rate parameter value of 5.

Multiplexing capacity

To estimate multiplexing capacity, we used locus-level read counts from the sequencing

dataset generated in this study. Total on-target reads per sample and locus-specific

read proportions were calculated, and relative sample efficiencies were derived to

capture uneven sample representation in multiplexed libraries. We then used empirically

parameterized Monte Carlo resampling to model expected locus coverage across

Illumina sequencing kits with different read outputs. For each kit and candidate multiplex

level, we assumed that 30% of reads would be lost (10% due to PhiX and 20% due to

off-target amplification). We repeated the resampling procedure 100 times. Samples

were considered to pass if at least 75% of loci achieved ≥10 reads, and recommended

multiplexing levels were defined as the largest sample number for which ≥80% of

samples were predicted to meet this criterion. Additional details are provided in

Supplemental Text 5.

Results

Panel characteristics

228 Windows selected during panel design were chosen based on high nucleotide diversity

229 and/or high F_{ST}. Consistent with these criteria, all windows included in the final marker

230 set exhibited high mean nucleotide diversity (median = 0.7552; IQR = 0.5555-0.9803;

231 Figure 1A) and/or high mean F_{ST} (median = 0.4555, IQR = 0.31-0.5964; Figure 1B) in

232 the genome set used for panel design.

233 Panel evaluation with field samples

Detailed results for the samples used for laboratory workflow optimization are described

in Supplemental Text 2. In brief, both extraction methods performed similarly, and

differences between enrichment strategies were modest. SWGA yielded a slightly

higher proportion of on-target reads, whereas targeted pre-amplification resulted in

slightly more even coverage across markers. SWGA and the Chelex/saponin method

were selected for the final protocol.

In the serial dilution experiments, mean read counts across replicates (Supplemental

Figure 1) indicate that overall amplification was satisfactory (median read depth per

marker of 82; IQR = 22-391). A few loci exhibited lower amplification efficiency. Notably,

these loci performed well in prior experiments (Supplemental Text 2), suggesting that

this reduced performance is unlikely to represent intrinsic issues with the primers.

Despite the reduced sequencing output at these loci, the proportion of targets with a

minimum of 10 reads remained above 75% among all dilutions (Figure 2), suggesting

the SWGA protocol enables reliable amplification in low parasite copy number samples.

Moreover, off-target reads were low, with a median of 79.75% on-target reads per

sample (IQR = 71.68-80.85%).

Detection of minority alleles across replicates was inconsistent, though not strongly

affected by parasite copy number (Supplemental Figure 2). Concordance among

replicate pairs ranged widely, from nearly 0 to 1 when computed only on alleles present

in both replicates of the pair (Supplemental Figure 3). Notably, concordance varied

substantially among samples, possibly reflecting the presence of minor parasite strains

at low densities or variation introduced during dilution preparation. When alleles only

found in one replicate were included, concordance ranged from 0 to 0.6.

259 Panel evaluation with paneljudge and MalariaGEN data

Comparison of the PvGAP panel with the panels from Kleinecke et al. and PvGTseq

revealed that cardinalities (i.e., the number of unique alleles at each target) followed a

similar pattern, with most markers showing a cardinality below 10 in most populations

(Figure 3). Larger panels tended to have more high cardinality markers, though;

PvGTSeq contains several markers with a cardinality above 20. In all panels, target

effective cardinalities were fairly close to their theoretical maximum, the cardinality,

suggesting the targets have sufficient allelic evenness to be informative for relatedness

analyses (Figure 3).

The paneljudge simulations indicate all three panels have substantial power for

relatedness estimation. The RMSEs of $\hat{r}$ were 0.0625 to 0.125 for data-generating r

values between 0.15 and 0.75 and lower for data-generating r values near zero or one

(Figure 4). Similarly, the 95% confidence interval widths of these $\hat{r}$ estimates tend to be

wider (0.2-0.6) for intermediate data-generating r values and narrower near zero and

one (Supplemental Figure 4). As expected from the number of diversity markers,

PvGTSeq consistently yielded the lowest RMSE, followed by the Kleinecke et al. panel,

followed by PvGAP. The differences are larger for intermediate data-generating r values

and negligible for a data-generating r value of 0.99, indicating all panels are equally

equipped to identify clonal pairs. PvGTSeq and PvGAP exhibit little difference in

performance between geographic regions; the Kleinecke et al. panel exhibits slightly

better performance in Southeast Asia than Ethiopia or Latin America. Notably, in all

instances, for all panels, the 95% confidence interval widths are substantially less than

one.

Multiplexing capacity and sequencing cost

Based on sample-to-sample unevenness, on-target read percentages, and locus-

specific read counts observed in our dataset, we simulated multiplexing performance

across Illumina sequencing kits to estimate feasible multiplexing levels and associated

costs. For the Miseq v2 platform, the recommended multiplexing level is 136 samples

per run, corresponding to an estimated sequencing cost of 13.24 USD per sample and a

combined library preparation and sequencing cost of 28.24 USD per sample. Additional

details and results for other sequencing kits are described in Supplemental Text 5.

Discussion

PvGAP represents a cost-effective approach to targeted sequencing of *P. vivax*

microhaplotypes for genomic epidemiology applications in varied geographic locations.

The panel consists of 88 loci, including 80 selected for population genetic and

relationship inference and eight within genes of epidemiological interest (e.g., potential

drug resistance/tolerance markers). Our assay consistently yields reliable sequencing

depth and breadth of coverage, even in the case of samples with low parasite copy

numbers (10 parasites/µL), and does not rely on proprietary reagents. *In silico*

evaluation with MalariaGEN data and paneljudge demonstrates that PvGAP contains

sufficient marker diversity for relatedness estimation in a variety of geographic regions,

albeit with lower accuracy than larger panels.

PvGAP displayed strong sequencing performance in terms of proportion of successfully

amplified loci (all serial dilutions achieved >75% loci with ≥10× coverage) and

percentage of on-target reads (median 79.75%). The former metric compares favorably

to similar assays (Kleinecke et al. and PvGTseq). Multiplexing levels and on-target read

percentages were not consistently reported by Kleinecke et al. (2025) and Manrique-

Valverde et al. (2025), limiting direct comparison of sequencing efficiency and scalability

of assays, particularly for DBS-derived samples. Regarding reproducibility across

technical replicates, major allele detection was highly reproducible, but concordance of

WSAFs varied among samples. This result may stem from stochastic detection of low-

frequency minority clones, but this cannot be confirmed as these are field samples with

unknown true WSAFs. Future benchmarking with synthetic mixtures could clarify

interpretation of WSAF estimates and the need for further methodological refinements, if

any.

In terms of relatedness estimation, the paneljudge analysis showed good performance

of PvGAP, albeit slightly worse than similar, larger panels. All three panels evaluated

(PvGAP, PvGTSeq, and Kleinecke et al) perform well when the true relatedness is high

or low and somewhat worse when the true relatedness is intermediate (between 0.15

and 0.75). Although PvGTSeq consistently yielded the lowest RMSE, and PvGAP the

highest RMSE (ranging from 0.028 to 0.125 depending on relatedness level and

region), the importance of reducing RMSE should be evaluated in light of study

objectives, budgetary considerations, and the biological limits inherent to malaria

transmission inference. At present, the degree of precision required to reliably

distinguish specific transmission events remains incompletely defined and likely varies

by epidemiological setting and sampling design. Further empirical and simulation-based

work is needed to determine the added value of sequencing larger, more costly panels

that enable more accurate relatedness estimates.

Regarding cost, PvGAP is an affordable and flexible option. Library preparation for

PvGAP is approximately 13 USD per sample (excluding primer costs; see below),

compared to roughly 10-20 USD (converted from AUD) for the Kleinecke et al. (2025)

assay, depending on whether the PCR reaction volume is halved. Once sequencing is

included, we estimate a combined cost of approximately 28 USD per sample for PvGAP

in a Miseq v2 run. Manrique-Valverde et al. (2025) report an estimated cost of

approximately 39 USD per sample for library preparation and sequencing for PvGTSeq.

Primer synthesis constitutes an upfront cost that scales with the number of targets. We

estimate each locus requires approximately 24 USD in primer synthesis. Assuming the

same cost for PvGTSeq, initial investment increases by several thousand USD. Finally,

like the PvGTseq panel, the PvGAP primers have been designed to minimize cross-talk

during multiplexing and library preparation by relying on standard amplicon-based

methods rather than vendor-specific capture chemistries. In contrast, the Kleinecke

assay relies on IDT's proprietary rhAmpSeq methodology (Kleinecke et al., 2025), which

may influence cost structure, supply-chain flexibility, and implementation considerations.

PvGAP is a moderately-sized panel for *P. vivax* epidemiology that provides a practical

balance of feasibility and resolution for relatedness inference. In comparison to similar,

previously-published panels, PvGAP offers competitive cost, slightly worse accuracy for

relatedness estimation due to fewer markers, and a flexible laboratory protocol that can

be adapted to a variety of settings. By substantially expanding the array of available

panels, PvGAP helps ensure that the appropriate tool will be available for every

application of genomic epidemiology to *vivax* malaria.

Author Contributions

AH, EHS, and GY conceived of the study. DY and GY oversaw sample collection. EHS and ES designed the amplicon panel. LB, BJ, and EHS performed the laboratory work. AH performed data analyses and drafted the manuscript. DJ, EL, and EHS contributed to the interpretation of results. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

Acknowledgements

We thank the study participants and the field team of the International Centers of Excellence for Malaria Research (ICEMR) program for their involvement in this study.

Funding Sources

This work was supported by NIH grants U19AI129326, F32AI147460, R21AI190606, and R01AI162947 and the Lucille P. and Edward C. Giles Dissertation-Year Fellowship.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The code necessary to generate all figures from the raw data is available on GitHub

(https://github.com/a-hubbard/vivax_microhap) and Zenodo (will upload and include link

once accepted). The raw sequence reads from the serial dilution experiment are

available on SRA under Accession # PRJNA1435528. The references for the genomes

used in panel design are described in Table 1, and the genomes used in panel

evaluation were obtained from https://www.malariagen.net/resource/30/.

References

Anstey, N. M., Douglas, N. M., Poespoprodjo, J. R., & Price, R. N. (2012). Plasmodium vivax: Clinical spectrum, risk factors and pathogenesis. In *Advances in Parasitology* (Vol. 80, pp. 151–201).

Auburn, S., Benavente, E. D., Miotto, O., Pearson, R. D., Amato, R., Grigg, M. J., Barber, B. E., William, T., Handayuni, I., Marfurt, J., Trimarsanto, H., Noviyanti, R., Sriprawat, K., Nosten, F., Campino, S., Clark, T. G., Anstey, N. M., Kwiatkowski, D. P., & Price, R. N. (2018). Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics. *Nature Communications*, *9*(1), 2585. https://doi.org/10.1038/s41467-018-04965-4

Auburn, S., Böhme, U., Steinbiss, S., Trimarsanto, H., Hostetler, J., Sanders, M., Gao, Q., Nosten, F., Newbold, C. I., Berriman, M., Price, R. N., & Otto, T. D. (2016). A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. *Wellcome Open Research*, *1*, 4. https://doi.org/10.12688/wellcomeopenres.9876.1

Auburn, S., Campino, S., Miotto, O., Djimde, A. A., Zongo, I., Manske, M., Maslen, G., Mangano, V., Alcock, D., MacInnis, B., Rockett, K. A., Clark, T. G., Doumbo, O. K., Ouédraogo, J. B., & Kwiatkowski, D. P. (2012). Characterization of within-host Plasmodium falciparum diversity using next-generation sequence data. *PloS One*, *7*(2), e32891. https://doi.org/10.1371/journal.pone.0032891

Auburn, S., Getachew, S., Pearson, R. D., Amato, R., Miotto, O., Trimarsanto, H., Zhu, S. J., Rumaseb, A., Marfurt, J., Noviyanti, R., Grigg, M. J., Barber, B., William, T., Goncalves, S. M., Drury, E., Sriprawat, K., Anstey, N. M., Nosten, F., Petros, B., … Price, R. N.

398 (2019). Genomic Analysis of Plasmodium vivax in Southern Ethiopia Reveals Selective

399 Pressures in Multiple Parasite Mechanisms. *The Journal of Infectious Diseases*, *220*(11),

400 1738–1749. https://doi.org/10.1093/infdis/jiz016

401 Callahan, B. J., McMurdie, P. J., Rosen, M. J., Han, A. W., Johnson, A. J. A., & Holmes, S. P.

402 (2016). DADA2: High-resolution sample inference from Illumina amplicon data. *Nature*

403 *Methods*, *13*(7), 581–583. https://doi.org/10.1038/nmeth.3869

404 Campbell, N. R., Harmon, S. A., & Narum, S. R. (2015). Genotyping-in-Thousands by

405 sequencing (GT-seq): A cost effective SNP genotyping method based on custom

406 amplicon sequencing. *Molecular Ecology Resources*, *15*(4), 855–867.

407 https://doi.org/10.1111/1755-0998.12357

408 Chen, S.-B., Wang, Y., Kassegne, K., Xu, B., Shen, H.-M., & Chen, J.-H. (2017). Whole-

409 genome sequencing of a Plasmodium vivax clinical isolate exhibits geographical

410 characteristics and high genetic variation in China-Myanmar border area. *BMC*

411 *Genomics*, *18*(1), 131. https://doi.org/10.1186/s12864-017-3523-y

412 Cowell, A. N., Loy, D. E., Sundararaman, S. A., Valdivia, H., Fisch, K., Lescano, A. G.,

413 Baldeviano, G. C., Durand, S., Gerbasi, V., Sutherland, C. J., Nolder, D., Vinetz, J. M.,

414 Hahn, B. H., & Winzeler, E. A. (2017). Selective Whole-Genome Amplification Is a

415 Robust Method That Enables Scalable Whole-Genome Sequencing of Plasmodium vivax

416 from Unprocessed Clinical Samples. *mBio*, *8*(1), e02257-16.

417 https://doi.org/10.1128/mBio.02257-16

418 Cowell, A. N., Valdivia, H. O., Bishop, D. K., & Winzeler, E. A. (2018). Exploration of

419 Plasmodium vivax transmission dynamics and recurrent infections in the Peruvian

Amazon using whole genome sequencing. *Genome Medicine*, *10*(1), 52.

https://doi.org/10.1186/s13073-018-0563-0

Danecek, P., Bonfield, J. K., Liddle, J., Marshall, J., Ohan, V., Pollard, M. O., Whitwham, A.,

Keane, T., McCarthy, S. A., Davies, R. M., & Li, H. (2021). Twelve years of SAMtools

and BCFtools. *GigaScience*, *10*(2), giab008. https://doi.org/10.1093/gigascience/giab008

Gerlovina, I., Gerlovin, B., Rodríguez-Barraquer, I., & Greenhouse, B. (2022). Dcifer: An IBD-

based method to calculate genetic distance between polyclonal infections. *Genetics*,

222(2). https://doi.org/10.1093/genetics/iyac126

Getachew, H., Demissew, A., Abossie, A., Habtamu, K., Wang, X., Zhong, D., Zhou, G., Lee,

M.-C., Hemming-Schroeder, E., Bradley, L., Degefa, T., Hawaria, D., Tsegaye, A.,

W.Kazura, J., Koepfli, C., Yan, G., & Yewhalaw, D. (2023). Asymptomatic and

submicroscopic malaria infections in sugar cane and rice development areas of Ethiopia.

Malaria Journal, *22*(1), 341. https://doi.org/10.1186/s12936-023-04762-5

Githure, J. I., Yewhalaw, D., Atieli, H., Hemming-Schroeder, E., Lee, M.-C., Wang, X., Zhou,

G., Zhong, D., King, C. L., Dent, A., Mukabana, W. R., Degefa, T., Hsu, K., Githeko, A.

K., Okomo, G., Dayo, L., Tushune, K., Omondi, C. O., Taffese, H. S., … Yan, G. (2022).

Enhancing Malaria Research, Surveillance, and Control in Endemic Areas of Kenya and

Ethiopia. *The American Journal of Tropical Medicine and Hygiene*, *107*(4_Suppl), 14–

20. https://doi.org/10.4269/ajtmh.21-1303

Kattenberg, J. H., Cabrera-Sosa, L., Figueroa-Ildefonso, E., Mutsaers, M., Monsieurs, P.,

Guetens, P., Infante, B., Delgado-Ratto, C., Gamboa, D., & Rosanas-Urgell, A. (2024).

Plasmodium vivax genomic surveillance in the Peruvian Amazon with Pv AmpliSeq

assay. *PLoS Neglected Tropical Diseases*, *18*(7), e0011879.

https://doi.org/10.1371/journal.pntd.0011879

Kattenberg, J. H., Nguyen, H. V., Nguyen, H. L., Sauve, E., Nguyen, N. T. H., Chopo-Pizarro,

A., Trimarsanto, H., Monsieurs, P., Guetens, P., Nguyen, X. X., Esbroeck, M. V.,

Auburn, S., Nguyen, B. T. H., & Rosanas-Urgell, A. (2022). Novel highly-multiplexed

AmpliSeq targeted assay for Plasmodium vivax genetic surveillance use cases at multiple

geographical scales. *Frontiers in Cellular and Infection Microbiology*, *12*, 953187.

https://doi.org/10.3389/fcimb.2022.953187

Kleinecke, M., Sutanto, E., Rumaseb, A., Hoon, K. S., Trimarsanto, H., Osborne, A., Manrique,

P., Peters, T., Hawkes, D., Benavente, E. D., Whitton, G., Siegel, S. V., Pearson, R. D.,

Amato, R., Rai, A., Nhien, N. T. T., Nguyen, H. C., Assefa, A., Degaga, T. S., …

Auburn, S. (2025). Microhaplotype deep sequencing assays to capture Plasmodium vivax

infection lineages. *Nature Communications*, *16*(1), 7192. https://doi.org/10.1038/s41467-

025-62357-x

Koepfli, C., & Mueller, I. (2017). Malaria Epidemiology at the Clone Level. *Trends in*

Parasitology, *33*(12), 974–985. https://doi.org/10.1016/j.pt.2017.08.013

LaVerriere, E., Schwabl, P., Carrasquilla, M., Taylor, A. R., Johnson, Z. M., Shieh, M., Panchal,

R., Straub, T. J., Kuzma, R., Watson, S., Buckee, C. O., Andrade, C. M., Portugal, S.,

Crompton, P. D., Traore, B., Rayner, J. C., Corredor, V., James, K., Cox, H., … Neafsey,

D. E. (2022). Design and implementation of multiplexed amplicon sequencing panels to

serve genomic epidemiology of infectious disease: A malaria case study. *Molecular*

Ecology Resources, *22*(6), 2285–2303. https://doi.org/10.1111/1755-0998.13622

Lee, P. C., Chong, E. T. J., Anderios, F., AL Lim, Y., Chew, C. H., & Chua, K. H. (2015).

Molecular detection of human Plasmodium species in Sabah using PlasmoNex[TM]

multiplex PCR and hydrolysis probes real-time PCR. *Malaria Journal*, *14*(1), 28.

https://doi.org/10.1186/s12936-015-0542-5

Lo, E., Hostetler, J. B., Yewhalaw, D., Pearson, R. D., Hamid, M. M. A., Gunalan, K., Kepple,

D., Ford, A., Janies, D. A., Rayner, J. C., Miller, L. H., & Yan, G. (2019). Frequent

expansion of Plasmodium vivax Duffy Binding Protein in Ethiopia and its

epidemiological significance. *PLOS Neglected Tropical Diseases*, *13*(9), e0007222.

https://doi.org/10.1371/journal.pntd.0007222

MalariaGEN, Adam, I., Alam, M. S., Alemu, S., Amaratunga, C., Amato, R., Andrianaranjaka,

V., Anstey, N. M., Aseffa, A., Ashley, E., Assefa, A., Auburn, S., Barber, B. E., Barry,

A., Batista Pereira, D., Cao, J., Chau, N. H., Chotivanich, K., Chu, C., … Yilma, D.

(2022). An open dataset of Plasmodium vivax genome variation in 1,895 worldwide

samples. *Wellcome Open Research*, *7*, 136.

https://doi.org/10.12688/wellcomeopenres.17795.1

Manrique-Valverde, P. C., Hasund, C. M., Kelley, K. A., Amaya-Romero, J.-E., Arévalo-

Herrera, M., Brosula, R., Calzada, J., Chenet, S. M., Corredor, V., Early, A. M.,

Fontecha, G., Forero-Peña, D. A., Herrera, S., Lana, J. T., Laws, M., Niles-Robin, R.,

Obaldia, N., Santamaria, A. M., Schwabl, P., … Neafsey, D. E. (2025). *PvGTSeq and*

PvCRiSP: Two amplicon-based targeted sequencing panels for Plasmodium vivax (p.

2025.11.04.25339464). medRxiv. https://doi.org/10.1101/2025.11.04.25339464

Menard, D., Chan, E. R., Benedet, C., Ratsimbasoa, A., Kim, S., Chim, P., Do, C., Witkowski,

B., Durand, R., Thellier, M., Severini, C., Legrand, E., Musset, L., Nour, B. Y. M.,

Mercereau-Puijalon, O., Serre, D., & Zimmerman, P. A. (2013). Whole Genome

Sequencing of Field Isolates Reveals a Common Duplication of the Duffy Binding

Protein Gene in Malagasy Plasmodium vivax Strains. *PLOS Neglected Tropical*

Diseases, *7*(11), e2489. https://doi.org/10.1371/journal.pntd.0002489

Neafsey, D. E., Taylor, A. R., & MacInnis, B. L. (2021). Advances and opportunities in malaria

population genomics. *Nature Reviews. Genetics*, (22), 502–517.

https://doi.org/10.1038/s41576-021-00349-5

Oyola, S. O., Ariani, C. V., Hamilton, W. L., Kekre, M., Amenga-Etego, L. N., Ghansah, A.,

Rutledge, G. G., Redmond, S., Manske, M., Jyothi, D., Jacob, C. G., Otto, T. D., Rockett,

K., Newbold, C. I., Berriman, M., & Kwiatkowski, D. P. (2016). Whole genome

sequencing of Plasmodium falciparum from dried blood spots using selective whole

genome amplification. *Malaria Journal*, *15*(1), 597. https://doi.org/10.1186/s12936-016-

1641-7

Parobek, C. M., Lin, J. T., Saunders, D. L., Barnett, E. J., Lon, C., Lanteri, C. A.,

Balasubramanian, S., Brazeau, N., DeConti, D. K., Garba, D. L., Meshnick, S. R., Spring,

M. D., Chuor, C. M., Bailey, J. A., & Juliano, J. J. (2016). Selective sweep suggests

transcriptional regulation may underlie Plasmodium vivax resilience to malaria control

measures in Cambodia. *Proceedings of the National Academy of Sciences of the United*

States of America, *113*(50), E8096–E8105. https://doi.org/10.1073/pnas.1608828113

Popkin-Hall, Z. R., Niaré, K., Crudale, R., Simkin, A., Fola, A. A., Sanchez, J. F., Pannebaker,

D. L., Giesbrecht, D. J., Kim, I. E., Aydemir, Ö., Bailey, J. A., Valdivia, H. O., &

Juliano, J. J. (2024). High-throughput genotyping of Plasmodium vivax in the Peruvian

Amazon via molecular inversion probes. *Nature Communications*, *15*(1), 10219.

https://doi.org/10.1038/s41467-024-54731-y

Rosado, J., Han, J., Obadia, T., Munro, J., Traore, Z., Schoffer, K., Brewster, J., Bourke, C.,

Vinetz, J. M., White, M., Bahlo, M., Gamboa, D., Mueller, I., & Ruybal-Pesántez, S.

(2025). *Understanding Plasmodium vivax recurrent infections using an amplicon deep*

sequencing assay, PvAmpSeq, identity-by-descent and model-based classification (p.

2025.05.26.25327775). medRxiv. https://doi.org/10.1101/2025.05.26.25327775

Shen, H.-M., Chen, S.-B., Wang, Y., Xu, B., Abe, E. M., & Chen, J.-H. (2017). Genome-wide

scans for the identification of Plasmodium vivax genes under positive selection. *Malaria*

Journal, *16*(1), 238. https://doi.org/10.1186/s12936-017-1882-0

Signorell, A. (2025). *DescTools: Tools for Descriptive Statistics* (Version 0.99.59) [Computer

software]. https://github.com/AndriSignorell/DescTools/

Taylor, A. R., Jacob, P. E., Neafsey, D. E., & Buckee, C. O. (2019). Estimating Relatedness

Between Malaria Parasites. *Genetics*, *212*(4), 1337–1351.

https://doi.org/10.1534/genetics.119.302120

Tessema, S. K., Hathaway, N. J., Teyssier, N. B., Murphy, M., Chen, A., Aydemir, O., Duarte,

E. M., Simone, W., Colborn, J., Saute, F., Crawford, E., Aide, P., Bailey, J. A., &

Greenhouse, B. (2022). Sensitive, Highly Multiplexed Sequencing of Microhaplotypes

From the Plasmodium falciparum Heterozygome. *The Journal of Infectious Diseases*,

225(7), 1227–1237. https://doi.org/10.1093/infdis/jiaa527

Twohig, K. A., Pfeffer, D. A., Baird, J. K., Price, R. N., Zimmerman, P. A., Hay, S. I., Gething,

P. W., Battle, K. E., & Howes, R. E. (2019). Growing evidence of Plasmodium vivax

across malaria-endemic Africa. *PLoS Neglected Tropical Diseases*, *13*(1), e0007140.

https://doi.org/10.1371/journal.pntd.0007140

Winter, D. J., Pacheco, M. A., Vallejo, A. F., Schwartz, R. S., Arevalo-Herrera, M., Herrera, S.,

Cartwright, R. A., & Escalante, A. A. (2015). Whole Genome Sequencing of Field

Isolates Reveals Extensive Genetic Diversity in Plasmodium vivax from Colombia.

PLOS Neglected Tropical Diseases, *9*(12), e0004252.

https://doi.org/10.1371/journal.pntd.0004252

Yan, G., Lee, M.-C., Zhou, G., Jiang, A.-L., Degefa, T., Zhong, D., Wang, X., Hemming-

Schroeder, E., Mukabana, W. R., Dent, A. E., King, C. L., Hsu, K., Beeson, J., Githure, J.

I., Atieli, H., Githeko, A. K., Yewhalaw, D., & Kazura, J. W. (2022). Impact of

Environmental Modifications on the Ecology, Epidemiology, and Pathogenesis of

Plasmodium falciparum and Plasmodium vivax Malaria in East Africa. *The American*

Journal of Tropical Medicine and Hygiene, *107*(4_Suppl), 5–13.

https://doi.org/10.4269/ajtmh.21-1254

Captions

Figures

Figure 1: Mean nucleotide diversity **(A)** and mean F_{ST} **(B)** for the genome windows selected for inclusion in the final panel.

Figure 2: Scatterplot showing the relationship between parasite copy number and the percentage of loci with 10 or more reads (indicating successful amplification) for each replicate of the serial dilutions. The *x*-axis is $\log_{10}$ scaled. The blue line is a simple linear regression, with shaded areas showing 95% confidence intervals. The horizontal red line indicates 75% successful amplification, a common threshold for resequencing a sample.

Figure 3: Cardinality (the number of unique alleles) versus effective cardinality (the number of unique alleles adjusted for allele frequency) for each marker (horizontal ticks indicate markers), based on the MalariaGEN data. The diagonal line shows *y=x*, which is the theoretical maximum of effective cardinality. The facets show the markers separately for each panel and population.

Figure 4: The RMSE of $\hat{r}$ for each data-generating *r* value, as simulated by paneljudge. Facets distinguish results for different populations. Line and point colors indicate different marker panels.